60+ Presentations from Top Biopharma in 2025

Advancing T Cell Engager Therapies: Mechanistic Insights and Translational Perspectives on Glofitamab
Marina Bacac, PhD, Head, Cancer Immunotherapy, Roche Innovation Center

Challenges of Using Ultralow Concentrated Clinical Products in MABEL Studies
Karoline B. Bechtold-Peters, PhD, Director, Science & Technology, Drug Product Development Biologics, Novartis Pharma AG

ML Models for Nanobody Developability Trained on a Purpose-Built Multi-Readout Dataset
Lasse M. Blaabjerg, PhD, Scientist, Genmab

Engineered Antibodies for Delivery of Nucleic Acids to the Brain
Ulrich Brinkmann, PhD, Expert Scientist, Pharma Research & Early Development, Roche Innovation Center

Innovating T Cell Engager Therapy
Mark Cobbold, PhD, Vice President, Oncology Early Discovery, AstraZeneca Pharmaceuticals

Engineering Approaches to Address Safety and Efficacy Challenges of T Cell Engagers
Javier Chaparro-Riggers, PhD, Executive Director, BioMedicine Design, Pfizer Inc.

In vivo Disulfide Bond Stability—A Critical Factor for PK and PD Profiles of Insulins
Christian N. Cramer, Senior Principal Scientist, Discovery ADME, Novo Nordisk A/S

Designing and Analysis of a Large Library-on-Library Dataset to Reveal Insights on Protein Stability across Different VHH:Antigen Complexes
Jurrian de Kanter, PhD, Data Scientist, Genmab

Discovery and Characterisation of AZD5335, a FRα-Targeted TOP1i-Loaded ADC
Roger B. Dodd, PhD, Director, Biologics Engineering, AstraZeneca

Taking T Cell Engagement to the Next Level: Generating CD8-Selective T Cell Engagers with the TITAN Framework
Simon Dovedi, PhD, Executive Director, Head of Discovery Immune Cell Engagement (UK), ICC, Oncology R&D, AstraZeneca

AI-Driven Optimisation of Antibody Properties: Opportunities and Challenges
Andreas Evers, PhD, Associate Scientific Director, Antibody Discovery & Protein Engineering, Global Research & Development Discovery Technology, Merck Healthcare KGaA

Utilising Learnings from High-Throughput Protein Expression Platforms to Enhance Delivery of Fit-for-Purpose Reagents
Helena Maja Firczuk, PhD, Group Leader, Protein and Cellular Sciences, GSK

Lab-in-the-Loop Application for Clinically Relevant Antigen Targets
Nathan Frey, PhD, Senior Machine Learning Scientist, Prescient Design, a Genentech Company

Computational Strategies for Mono- and Multi-Valent VHH/Nanobody Developability Assessment
Norbert Furtmann, PhD, Head, Computational and High-Throughput Protein Engineering, Large Molecule Research, Sanofi

Miniaturised Target Protein Affinity Chromatography-Mass Spectrometry for Structure-Function Characterisation of Therapeutic Antibodies
Christian Graf, PhD, Fellow, Scientific Office, Novartis Technical R&D Biologics

Engineered Antibodies for Pre-Targeted Radiotherapy
Alexander Haas, PhD, Head, Biologics Core Technologies, Roche Diagnostics GmbH

Antibody-Oligonucleotide Conjugates: Design, Developability, and Activity
Maximilian Hartl, PhD, Scientist & Lab Manager, Pharma Research & Early Development, Roche Diagnostics GmbH

New Approaches for Process Analytics—From mAbs to Multispecifics
Dirk Haubert, PhD, Associate Director, Biologics, Novartis Pharma AG

A Novel ATP-Dependent FcγRs Affinity-Enhanced Anti-CTLA-4 Switch Antibody for Tumour-Selective Enhancement of Anti-Tumour Immunity
Hiroki Hayashi, Researcher, Discovery Pharmacology, Chugai Pharmaceutical Co Ltd.

DyAb: Sequence-Based Antibody Design and Property Prediction in a Low-Data Regime
Jen Hofmann, PhD, Senior ML Scientist, Prescient Design, Genentech

Emerging Immunogenicity Challenges for Next-Generation Biotherapeutics
Andreas Hollenstein, PhD, Principal Scientist, Immunosafety, Roche

FAIR Data to Predict Recombinant Protein Expression
Lovisa Holmberg Schiavone, PhD, Director, Protein Sciences, Structure & Biophysics, Discovery Sciences, R&D, AstraZeneca

Evaluation of Digital Protein Design Tools in an Industry Setting
Karin Hrovatin, Bioinformatic Scientist, Merck KGaA
Stephanie Linker, PhD, Senior Computational Biochemist, Merck Group

Interrogation of Hypoxia-Induced Effects on the Tumour Microenvironment Using Live Imaging in 3D Spheroid Models
Bushra Husain, PhD, Director of Assay, Profiling, and Pharmacology, AstraZeneca

Predictive Stability for Biologics: Opportunities & Challenges
Andrea Junyan Ji, PhD, Senior Scientist, Pharmaceutical Development, Genentech, Inc.

HexaBody-OX40: A Novel Fcyr Crosslinking-Independent OX40-Targeting Antibody with Agonistic Activity in vitro and Antitumour Activity in Vivo
Kristel Kemper, PhD, Scientist, Translational Research, Genmab BV

Advanced MS-Based Characterisation of Host Cell Proteins in Biotherapeutic Purification Workflows
Somar Khalil, PhD, Principal Scientist, Analytical Research & Development, GSK

Automated Sample Fractionation and Non-Reduced Multi-Enzyme Digestion Coupled with Nanoflow LC-MS/MS for Comprehensive Characterisation of Antibody-Drug Conjugates
Dan Bach Kristensen, PhD, Scientific Director, Symphogen

Comparative Analysis of Ala-scan, HDX, and Cryo-EM for Epitope Determination
Anand Kumar, PhD, Senior Scientist, Bio Structure and Biophysics, Integrated Drug Discovery, Sanofi

Engineering Affinity Attenuated and Effector CD8 Biased T Cell Engagers
Christopher Lloyd, PhD, Director, Biologics Engineering, AstraZeneca

Droplet Microfluidic Platform for Characterisation of Precipitation and Phase Separation of Biologics
Nikolai Lorenzen, PhD, Scientific Director, Biophysics and Injectable Formulation, Novo Nordisk AS

Closed Loop Autonomous Learning for Protein Engineering
James D. Love, PhD, Vice President, Cross Modality Workflows, Novo Nordisk AS

A Machine Learning Approach to Improving Antibody Developability
Paul MacDonald, PhD, Data Scientist, Protein Design Informatics, GSK

Producing Challenging Protein Targets for Drug Discovery
Hazel Mak, PhD, Senior Protein Scientist, Discovery Sciences R&D, AstraZeneca

Predicting Nonspecificity in Therapeutic Antibody Formats Using Structure-Informed Machine Learning Models
Paolo Marcatili, PhD, Head, Antibody Design, Novo Nordisk

Synergizing Cryo-EM and AI for Antibody Lead Optimisation
Juan Carlos Mobarec, PhD, Head Computational Structural Biology—Associate Director, Mechanistic and Structural Biology, Discovery Sciences, R&D, AstraZeneca

Antibody Expression Strategies to Meet Accelerated Timelines in Small Biotech
Dana Moreno Sanchez, Protein Expression Scientist, Alchemab Therapeutics

Strategy of Forced Degradation Study and Practical Uses of the Samples for Characterisation of the Products
Shusuke Nambu, PhD, Chief Scientist, Analytical Development Department, Chugai Pharmaceutical Co. Ltd.

An End-to-End Automated Workflow for Characterisation of Next-Generation Biotherapeutics
Miroslav Nikolov, PhD, Senior Scientist & Laboratory Head, Roche Pharma Research and Early Development pRED, Roche

Immunogenicity Risk Assessment for Biologics Drug Discovery & Development at AstraZeneca
Olga Obrezanova, PhD, Principal Scientist, Biologics Engineering, Oncology R&D, AstraZeneca

A Novel Long-Acting Relaxin-2 Fusion, AZD3427, Improves Cardiac Performance in Non-Human Primates with Cardiac Dysfunction
Monika Papworth, PhD, Principal Scientist, Biologics Engineering, AstraZeneca

Targeted Protein Degradation through Site-Specific Antibody Conjugation with Mannose 6-Phosphate Glycan
Anna Park, PhD, Head, Protein Engineering, Large Molecule Research US, Sanofi

Flow-Induced Dispersion Analysis Opens New Avenues for Peptide Screening
Marie Østergaard Pedersen, PhD, Principal Scientist, R&D, Novo Nordisk AS

Finding Antibodies with Cryo-EM Maps
Chiara Rapisarda, PhD, Group Leader, Sanofi

Identification and Quantification of Mispaired Species of Asymmetric Monovalent Bispecific IgG1 Monoclonal Antibody Format Using Reverse-Phase Polyphenyl Chromatography-Coupled Electrospray Ionisation Mass Spectrometry
Ryte Poskute, Senior Scientist, Analytical Sciences, AstraZeneca

Structural Insights into CXCR4 Modulation and Oligomerisation
Kei Saotome, PhD, Senior Principal Scientist, Structural Biology, Regeneron

Connecting Data, People, and Process: The Digital Transformation of Protein Production
Dominik Schneider, PhD, Senior Manager, R&D Enabling Technology, CSL Behring Innovation

The Complex Binding Mode of IgGs to the Fc Receptor Neonatal
Tilman Schlothauer, PhD, Senior Principal Scientist, Roche Diagnostics GmbH

In silico Developability for Biologics Engineering: Challenges and Successes
Isabelle Sermadiras, Associate Principal Scientist, AstraZeneca

Analytical Methods for Developing Co-Formulated Biopharmaceutical Dosage Forms: A Case Study
Ramesh Kumar Shanmugam, PhD, MBA, Associate Director, Biopharmaceutical Development, AstraZeneca

Structure-Aided Design and Engineering of an FGFR1c x KLB Multispecific Altibody Agonist for MASH
Yang Shen, PhD, Executive Director Antibody Engineering, Department of Bispecifics, Regeneron

Tumour-Targeted Costimulation via CD28 Bispecific Antibodies—Turning Immunotherapy "Cold" Tumour "Hot"
Dimitris Skokos, PhD, Vice President, Cancer Immunology, Regeneron Pharmaceuticals

Discovery, Design, and Optimisation of Antibody Modalities against a GPCR Target
Catharina Steentoft, PhD, Senior Scientist, Antibody Technology, Novo Nordisk

Virus-Like-Particle Production and Characterisation for Use in Biologics Discovery Campaigns
Amberley Stephens, PhD, Senior Protein Scientist, Biologics Engineering, AstraZeneca

Native Antigen Platforms (NAPs) for Membrane Protein Ab Discovery
Rajesh Sundaresan, PhD, Scientific Leader, Protein Cell and Structural Sciences, GSK

Antibody DomainBed: Out-of-Distribution Generalisation in Therapeutic Protein Design
Natasa Tagasovska, PhD, Principal Machine Learning Scientist and Scientific Manager, Prescient Design, Genentech, Roche

Elevating Success, Throughput, and Efficiency: Advancing Protein Purification with Platform Technologies and Automation
Sandeep K. Talapatra, PhD, Leader Protein Science, Protein Cell & Structural Sciences, GSK

Mitigation of Immunogenicity during Drug Design
Sophie Tourdot, PhD, Immunogenicity Sciences Lead, BioMedicine Design, Pfizer

Exploring Log-Likelihood Scores for Ranking Antibody Sequence Designs
Talip Ucar, Senior Director, AI Research, AstraZeneca

A Data-Driven Computational Pipeline for Screening HexElect Antibody Perturbations Using Cell Painting
Leon Van Gurp, PhD, Senior Data Scientist, Discovery Data Science, Genmab BV

Accelerating Drug Discovery: The Power of in silico-Assisted Antibody Discovery at Bayer
Vanessa Verissimo, Research Scientist, Therapeutic Antibodies, Bayer Pharma AG

Unlocking Developability: A Holistic Approach to Determine Structural-Functional Relationship for Drug Candidates
Paul Wassmann, PhD, Senior Principal Scientist, NIBR Biologics Center, Novartis

Machine Learning–Enabled Development of a Highly-Functional Venom Library Platform with Fast Hits-to-Leads Workflow for Peptide Therapeutics Discovery
Yingnan Zhang, PhD, Senior Principal Scientific Manager, Biological Chemistry, Genentech, Inc.

 

* As of 30 June 2025. Please see individual agenda pages for most up-to-date agenda.